Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9019949 | 0.65 | NPC1 (0.45) | CRBNNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL10989715 | 0.65 | ALDH1A1 (0.35) | LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL12462462 | 0.65 | PDPK1 (0.37) | CRBNLMNADDB1ALDH1A1 | |
| SCHEMBL25247849 | 0.64 | NPC1 (0.35) | CRBNNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL12668351 | 0.64 | CYP11B2 (0.38) | CRBNNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL21086729 | 0.64 | CRBN (0.37) | CRBNNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL4067867 | 0.64 | — | — | |
| SCHEMBL18366453 | 0.63 | CRBN (0.37) | CRBNDDB1 | |
| SCHEMBL9885810 | 0.62 | NPC1 (0.33) | CRBNNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL23034290 | 0.61 | CYP11B2 (0.33) | CRBNNPC1LMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161494-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | claimed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| EP-4161494-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-8192918-B2 | Lithographic printing plate precursor | AGFA GRAPHICS NV (BE) | 2012-06-05 | — | — | US | disclosed |
| US-8192918-B2 | Lithographic printing plate precursor | AGFA GRAPHICS NV (BE) | 2012-06-05 | — | — | US | disclosed |
| US-8192918-B2 | Lithographic printing plate precursor | AGFA GRAPHICS NV (BE) | 2012-06-05 | — | — | US | disclosed |
| EP-1985445-B1 | A lithographic printing plate precursor | AGFA GRAPHICS NV (BE) | 2011-07-20 | — | — | EP | disclosed |
| US-20100112476-A1 | A LITHOGRAPHIC PRINTING PLATE PRECURSOR | AGFA GRAPHICS NV (BE) | 2010-05-06 | — | — | US | disclosed |
| US-20100112476-A1 | A LITHOGRAPHIC PRINTING PLATE PRECURSOR | AGFA GRAPHICS NV (BE) | 2010-05-06 | — | — | US | disclosed |
| US-20100112476-A1 | A LITHOGRAPHIC PRINTING PLATE PRECURSOR | AGFA GRAPHICS NV (BE) | 2010-05-06 | — | — | US | disclosed |
| EP-1985445-A1 | A lithographic printing plate precursor | Agfa Graphics N.V. (BE) | 2008-10-29 | — | — | EP | disclosed |
| EP-1985445-A1 | A lithographic printing plate precursor | Agfa Graphics N.V. (BE) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, USP8, USP7 | CRBN 299/4885NPC1 2328/4885LMNA 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.